Search Results - "Tsurutani, J"

Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer by Yoshioka, H., Shimokawa, M., Seto, T., Morita, S., Yatabe, Y., Okamoto, I., Tsurutani, J., Satouchi, M., Hirashima, T., Atagi, S., Shibata, K., Saito, H., Toyooka, S., Yamamoto, N., Nakagawa, K., Mitsudomi, T.

“…Primary analysis of the phase III study WJTOG 3405 demonstrated superiority of progression-free survival (PFS) for gefitinib (G) in patients treated with the…”
Get full text

Eribulin as first- or second-line chemotherapy for advanced or metastatic HER2-negative breast cancer: A real-world prospective study by Takahashi, M., Inoue, K., Mukai, H., Yamanaka, T., Egawa, C., Sakata, Y., Ikezawa, H., Matsuoka, T., Tsurutani, J.

Get full text

Updated results of phase I study of trastuzumab deruxtecan (DS-8201a) in HER2-expressing advanced colorectal cancer by Yoshino, T, Iwata, H, Tamura, K, Takahashi, S, Redfern, C, Modi, S, Doi, T, Kawakami, H, Taniguchi, H, Takashima, A, Yamaguchi, K, Fisher, J, Li, B, Saito, K, Fujisaki, Y, Sugihara, M, Tsurutani, J

Get full text

A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer by Sakiyama, T, Tsurutani, J, Iwasa, T, Kawakami, H, Nonagase, Y, Yoshida, T, Tanaka, K, Fujisaka, Y, Kurata, T, Komoike, Y, Nishio, K, Nakagawa, K

“…Background: We evaluated the safety, maximum-tolerated dose (MTD), pharmacokinetics, recommended dose for phase II (P2RD), and preliminary anticancer activity…”
Get full text

2168 Predictive biomarker analysis of early tumor shrinkage induced by FOLFIRI+Bev for patients with metastatic colorectal cancer in WJOG4407G study by Tsuji, Y, Yamazaki, K, Oba, M. Saito, Sakai, K, Nagase, M, Ueda, S, Tamagawa, H, Tamura, T, Moriwaki, T, Murata, K, Taira, K, Denda, T, Funai, S, Tsuda, T, Tsushima, T, Boku, N, Hyodo, I, Yamanaka, T, Tsurutani, J, Nishio, K

Get full text

2152 Exploratory analysis of predictive biomarkers of oxaliplatin versus irinotecan in combination with bevacizumab for patients with metastatic colorectal cancer in WJOG4407G study by Fujita, Y, Yamazaki, K, Oba, M.S, Muro, K, Negoro, Y, Yoshida, M, Suyama, K, Kurimoto, T, Sugimoto, N, Seki, N, Sato, M, Ebi, M, Tamagawa, H, Ueda, S, Tamura, T, Boku, N, Hyodo, I, Yamanaka, T, Tsurutani, J, Nishio, K

Get full text

Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC by Takeda, Masayuki, Okamoto, Isamu, Tsurutani, Junji, Oiso, Naoki, Kawada, Akira, Nakagawa, Kazuhiko

“…Somatic mutations in the epidermal growth factor receptor gene are associated with a therapeutic response to epidermal growth factor receptor tyrosine kinase…”
Get full text

Zoledronic acid-induced regression of multiple metastases at nonskeletal sites by Okamoto, K., Tsurutani, J., Terashima, M., Okamoto, I., Nakagawa, K.

Get full text

Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer by KINOSHITA, A, FUKUDA, M, OKA, M, SODA, H, NAGASHIMA, S, FUKUDA, M, TAKATANI, H, KUBA, M, NAKAMURA, Y, TSURUTANI, J, KOHNO, S

“…To determine the efficacy and toxicity of irinotecan combined with carboplatin, we conducted a phase II trial. Eligibility criteria were: chemotherapy-naïve,…”
Get full text

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer by Modi, Shanu, Saura, Cristina, Yamashita, Toshinari, Park, Yeon Hee, Kim, Sung-Bae, Tamura, Kenji, Andre, Fabrice, Iwata, Hiroji, Ito, Yoshinori, Tsurutani, Junji, Sohn, Joohyuk, Denduluri, Neelima, Perrin, Christophe, Aogi, Kenjiro, Tokunaga, Eriko, Im, Seock-Ah, Lee, Keun Seok, Hurvitz, Sara A, Cortes, Javier, Lee, Caleb, Chen, Shuquan, Zhang, Lin, Shahidi, Javad, Yver, Antoine, Krop, Ian

“…In this single-group, phase 2 study, the use of trastuzumab deruxtecan resulted in a response in 60% of women with HER2-positive advanced breast cancer who had…”
Get full text

Re: Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non–Small-Cell Lung Cancer by Tsurutani, Junji, Dennis, Phillip A.

“…al. (1).JUNJI TSURUTANIPHILLIP A. DENNISREFERENCES(1) Cappuzzo F, Magrini E, Ceresoli GL, Bartolini S, Rossi E, Ludovini V, et al. Akt phosphorylation and…”
Get full text

Phase I study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small-cell lung cancer by Oka, M, Fukuda, M, Kuba, M, Ichiki, M, Rikimaru, T, Soda, H, Tsurutani, J, Nakamura, Y, Kawabata, S, Nakatomi, K, Narasaki, F, Nagashima, S, Takatani, H, Fukuda, M, Kinoshita, A, Kohno, S

“…We conducted a phase I study of irinotecan (CPT-11) and cisplatin with concurrent split-course radiotherapy in limited-disease small-cell lung cancer…”
Get full text

9002 A phase III, first-line trial of gefitinib versus cisplatin plusdocetaxel for patients with advanced or recurrent non-small cell lungcancer (NSCLC) harboring activating mutation of the epidermal growthfactor receptor (EGFR) gene: a preliminary results of WJTOG 3405 by Tsurutani, J, Mitsudomi, T, Mori, S, Okamoto, I, Kaname, N, Tada, H, Negoro, S, Yatabe, Y, Fukuoka, M, Nakagawa, K

Get full text

Phase I and pharmacokinetic study of paclitaxel and irinotecan for patients with advanced non-small cell lung cancer by Kasai, T, Oka, M, Soda, H, Tsurutani, J, Fukuda, M, Nakamura, Y, Kawabata, S, Nakatomi, K, Nagashima, S, Takatani, H, Fukuda, M, Kinoshita, A, Kohno, S

“…We conducted a phase I study of paclitaxel and irinotecan (CPT-11) in advanced non-small cell lung cancer (NSCLC). This study aimed to determine the maximum…”
Get full text

277P Phase II randomized study of trimebutine maleate and probiotics for abemaciclib-induced diarrhea in patients with HR-positive and HER2-negative advanced breast cancer (MERMAID) WJOG11318B by Masuda, H., Tanabe, Y., Matsumoto, K., Shimomura, A., Doi, M., Miyoshi, Y., Takahashi, M., Sagara, Y., Tokunaga, S., Iwasa, T., Niikura, N., Yoshimura, K., Takano, T., Tsurutani, J.

Get full text

217O Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC) by Ueno, N.T., Jacot, W., Yamashita, T., Sohn, J., Tokunaga, E., Prat, A., Tsurutani, J., Park, Y.H., Rugo, H.S., Xu, B., Cardoso, F., Mitri, Z., Mahtani, R., Dunton, K., Wang, Y., Gambhire, D., Cottone, F., Harbeck, N., Cameron, D.A., Modi, S.

Get full text

256P Difference of immunological status and response to immune checkpoint inhibitor between recurrent and de novo stage IV HER2-negative breast cancer in NEWBEAT trial (WJOG9917BTR) by Ozaki, Y., Kitano, S., Yamashita, M., Ikarashi, D., Tsurutani, J., Iwasa, T., Takahashi, M., Mukohara, T., Masuda, N., Futamura, M., Minami, H., Matsumoto, K., Tanabe Hashimoto, Y., Kawabata, H., Yoshimura, K., Takano, T.

Get full text

274TiP Datopotamab deruxtecan (Dato-DXd), a TROP2 antibody-drug conjugate, vs investigators’ choice of chemotherapy (ICC) in previously-treated, inoperable or metastatic hormone-receptor (HR) positive, HER2-negative (HR+/HER2–) breast cancer: TROPION-Breast01 by Bardia, A., Kalinsky, K., Tsurutani, J., Hamilton, E.P., Johnston, S., Sohn, J., Park, K.H., Park, Y.H., Im, S-A., Lee, K.S., Dastur, D., Haddad, V., Khan, S., Xu, B., Pistilli, B., Rugo, H.S.

Get full text

LBA11 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial by Bardia, A., Jhaveri, K., Im, S-A., Pernas Simon, S., De Laurentiis, M., Wang, S., Martinez, N., Santos Borges, G., Cescon, D.W., Hattori, M., Lu, Y-S., Hamilton, E.P., Zhang, Q.Y., Tsurutani, J., Kalinsky, K., Xu, L., Denduluri, N., Rugo, H.S., Xu, B., Pistilli, B.

Get full text

376O Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study by Modi, S., Jacot, W., Iwata, H., Park, Y.H., Losada, M.J. Vidal, Li, W., Tsurutani, J., Zaman, K., Ueno, N.T., Prat, A., Papazisis, K., Rugo, H.S., Harbeck, N., Im, S-A., De Laurentiis, M., Orbegoso, C.M.A., Yung, L., Cheng, F-C., Cheng, Y., Cameron, D.A.

Get full text